🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Learn about #BrainMetastases prevalence by therapy line and incidence of #BreastCancerBrainMetastases in this just published cohort study in JNCI. 👉pubmed.ncbi.nlm.nih.gov/40163696/ Dr Sarah Sammons Timothy Erick, PhD Filippo Montemurro Sara Tolaney #JosePabloLeone Nancy Lin, MD

📌Treatment deescalation for older women with favorable breast cancers: patient values and shared decision making academic.oup.com/jnci/advance-a… OncoAlert #OncoAlertAF

My daughter just presented me with the drawing of me that she made!! My heart is full❤️ #parenting #workingmom #medtwitter

Most people don’t understand how *new* most cancer treatments are. The treatment that cured my lymphoma was developed when I was a teenager. The treatments that will cure our children’s cancers are being put on hold right now.

2025 is “ADC year”. Two practice-changing ADC phase 3 trials announced to be positive. At least 6 more may read out this year, likely leading to further changes in the treatment of breast cancer. Exciting times!

The ultimate review on Right vs Left CRC. Must read for residents. doi.org/10.1038/s41698… Ashish Singh Prof Vikas Ostwal Dr Akhil Santhosh Dr Amol Akhade Anant Ramaswamy Valame MD DNB Pashtoon Kasi MD, MS

We’re often tempted to believe that diagnosing a recurrence earlier will improve outcomes. Clinical trials, however, suggest the opposite. We need new studies, with new tools (eg ctDNA) & implementation of new treatments. But we also need to inform pts adequately on this topic.

Advanced cancers returned to prepandemic levels, according to a reassuring report apnews.com/article/cancer… #MedTwitter #bcsm

Now out in #BCRT first clinical (and not reassuring) data on the potential gonadotoxic effect of adding #pembrolizumab to neoadjuvant #chemotherapy in patients with early triple-negative #BreastCancer OncoAlert YoungSurvivalCoaliti Tanja Spanic Europa Donna link.springer.com/article/10.100…

This is support important information about the mechanism of Enhertu (T’Dxd) ILD. Now how to decrease macrophage activity in the lungs without inhibiting anti-tumor immune responses? Go after the DAMPs, PRR, TLRs and CLRs? NFKB or STAT inhibitors?? #oncology #MedTwitter